A Phase III trial of MN-166 (ibudilast) in progressive multiple sclerosis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 May 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 May 2021 According to a MediciNova media release, the company is engaged in a process with potential partners regarding MN-166 that could lead to funding of this trial.
11 Jul 2019 According to a MediciNova media release, the company plans to conduct a single Phase 3 trial. The FDA acknowledged that a single trial can be the basis for marketing approval and the acceptability of a single trial to support drug approval depends on the study results. The FDA agreed that a population of subjects with secondary progressive MS without relapses is an appropriate target population.
06 Feb 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com